Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



GEN News Highlights

Back to Item »

Takeda Snags Cell Genesys’ Prostate Cancer Immunotherapy in $320M Agreement

All development and commercialization rights for this Phase III treatment will transfer to Takeda for $50 million upfront.

Forward this item to a colleague:
Your name
Your email
(Separate multiple addresses by commas)
 
Colleague's email
(Separate multiple addresses by commas)
 
Personal Message
(optional)
 
 
 

GEN Poll

More » Poll Results » Archive »

Myriad Genetics Trial: Your Thoughts?

Do you agree with the Supreme Court’s decision in the Myriad case?

Suggest a Poll